Last reviewed · How we verify
AT-501 High Dose vaccine with Adjuvant
AT-501 High Dose vaccine with Adjuvant is a Biologic drug developed by Medigen Vaccine Biologics Corp.. It is currently in Phase 1 development.
At a glance
| Generic name | AT-501 High Dose vaccine with Adjuvant |
|---|---|
| Sponsor | Medigen Vaccine Biologics Corp. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AT-501 High Dose vaccine with Adjuvant CI brief — competitive landscape report
- AT-501 High Dose vaccine with Adjuvant updates RSS · CI watch RSS
- Medigen Vaccine Biologics Corp. portfolio CI
Frequently asked questions about AT-501 High Dose vaccine with Adjuvant
What is AT-501 High Dose vaccine with Adjuvant?
AT-501 High Dose vaccine with Adjuvant is a Biologic drug developed by Medigen Vaccine Biologics Corp..
Who makes AT-501 High Dose vaccine with Adjuvant?
AT-501 High Dose vaccine with Adjuvant is developed by Medigen Vaccine Biologics Corp. (see full Medigen Vaccine Biologics Corp. pipeline at /company/medigen-vaccine-biologics-corp).
What development phase is AT-501 High Dose vaccine with Adjuvant in?
AT-501 High Dose vaccine with Adjuvant is in Phase 1.